Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU

Yoshitaka Honma; Nobuya Monden; Keisuke Yamazaki; Satoshi Kano; Hironaga Satake; Shigenori Kadowaki; Yoshitaka Utsumi; Tomohiko Nakatogawa; Ryo Takano; Koji Fujii; Yosuke Koroki; Junya Aoyama; Shohei Ouchi; Tetsuro Ogawa; Sharon McCarthy; Sabine Brookman‐May; Suneel Mundle; Jinhui Li; Daksh Thaper; Toshitaka Nagao; Yuichiro Tada

doi:10.1158/1078-0432.26790291

Abstract

Supplementary Materials for Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Honma et al. (2024) studied this question.

synapsesocial.com/papers/68e5bb1eb6db643587552ddd https://doi.org/10.1158/1078-0432.26790291

View Full Paper

Ask AI

Bookmark

Share

Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU

Abstract

Discussion

Cite This Study

Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers